Learn more

FORSSMANN WOLF GEORG

Overview
  • Total Patents
    64
About

FORSSMANN WOLF GEORG has a total of 64 patent applications. Its first patent ever was published in 1984. It filed its patents most often in Germany, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are APITOPE TECHNOLOGY BRISTOL LTD, HAEMOPEP PHARMA GMBH and EXOCELL INC.

Patent filings per year

Chart showing FORSSMANN WOLF GEORGs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Forssmann Wolf-Georg 39
#2 Adermann Knut 14
#3 Forssmann Wolf-Georg Prof Dr M 14
#4 Meyer Markus 14
#5 Schulz-Knappe Peter 13
#6 Maegert Hans-Juergen 10
#7 Richter Rudolf 6
#8 Nehls Michael 6
#9 Staendker Ludger 6
#10 Opitz Hans-Georg 6

Latest patents

Publication Filing date Title
DE10004667A1 New human defensin hBD3, useful as antibacterial, antifungal and antitumor agent, particularly for control of multi-resistant pathogens
DE19957043A1 New defensins
DE19951824A1 New N-terminal fragment of insulin-like growth factor binding protein-3 and its complexes with growth factors for treatment and diagnosis of e.g. muscular atrophy
DE19951471A1 Use of urodilatin for the treatment of chronic renal failure with residual kidney functions
WO0078963A1 Serin proteinase inhibitors
DE19903087A1 Treatment of erectile dysfunction with C-type natriuretic polypeptide (CNP) as monotherapy or in combination with phosphodiesterase inhibitors
CA2315976A1 Serine protease inhibitors
EP1042476A1 Insulin-like growth factor binding protein fragments and the utilization thereof
DE19842363A1 Use of chemokines, especially HCC-2 for mobilising haematopoietic stem cells, progenitor cells and mature leukocytes from the bone marrow into the blood stream
WO9914239A1 Composition for treating diabetes mellitus and obesity
DE19810515A1 Composition containing stimulators of cyclic nucleotide monophosphate
WO9837191A1 Human circulating hnlp (human neutrophil lymphocyte peptide)
DE19756678C1 Gene for murine odorant binding protein
US5891904A Use of inhibitors of phosphodiesterase IV
DE19730786A1 Human circulating hNLP (human neutrophil lymphocyte peptide)
WO9902161A1 Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
DE19632521A1 Isolating peptide(s) from body fluids, tissues and cell supernatant
EP0843553A1 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
DE19624802A1 Method for the direct diagnostic detection of pathogenic, genetically determined point mutations in proteins in heart diseases by chemical and physical methods, especially the direct and indirect coupling of high pressure liquid chromatography and mass spectrometry
DE19615710A1 Process for obtaining and using a biologically active protein - collagen fragment HF-COLL-18 / 514cf - in partially purified and synthetic form from body fluids to influence cell growth and the diagnosis of collagen diseases and osteoporosis